Cargando...
HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma
Although multiple myeloma (MM) patients benefit from standard bortezomib (BTZ) chemotherapy, they develop drug resistance, resulting in relapse. We investigated whether histone deacetylase 6 (HDAC6) inhibitor A452 overcomes bortezomib resistance in MM. We show that HDAC6-selective inhibitor A452 sig...
Guardado en:
| Publicado en: | Int J Mol Sci |
|---|---|
| Autores principales: | , , , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
MDPI
2021
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7866276/ https://ncbi.nlm.nih.gov/pubmed/33572814 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms22031341 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|